Evaluating Neuroprotection in Aneurysm Coiling Therapy (ENACT)

This study has been completed.
Sponsor:
Collaborator:
Arbor Vita Corporation
Information provided by (Responsible Party):
NoNO Inc.
ClinicalTrials.gov Identifier:
NCT00728182
First received: August 1, 2008
Last updated: August 9, 2013
Last verified: August 2013

August 1, 2008
August 9, 2013
August 2008
April 2011   (final data collection date for primary outcome measure)
Volume of New FLAIR Lesions(MRI) [ Time Frame: Enrolment, Days 2-4 ] [ Designated as safety issue: No ]
Volume of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose
To determine (1) the safety and tolerability of a single intravenous dose of NA-1 in patients undergoing endovascular repair of brain aneurysms and (2) the efficacy of NA-1 in reducing the volume of embolic strokes. [ Time Frame: Enrolment, Day 1, Days 2-4 and Day 30 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00728182 on ClinicalTrials.gov Archive Site
  • Number of New DWI Lesions (MRI) [ Time Frame: Enrolment, Day 2-4 ] [ Designated as safety issue: No ]
    Number of new ischemic lesions as defined by DWI MRI at 12-95 hours postdose.
  • Number of New FLAIR Lesions (MRI) [ Time Frame: Enrolment, Days 2-4 ] [ Designated as safety issue: No ]
    Number of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose.
  • Volume of New DWI Lesions (MRI) [ Time Frame: Enrolment, Days 2-4 ] [ Designated as safety issue: No ]
    Volume of new DWI lesions as defined by MRI at 12-95 hours postdose.
  • National Institutes of Health Stroke Scale (NIHSS). [ Time Frame: Enrolment, Day 30 ] [ Designated as safety issue: No ]
    The NIHSS is a standardized neurological method to measure disability and recovery after stroke. Scores range from 0 to 42, with higher scores indicating increasing severity. Scores were dichotomized into 0-1 (good outcome) versus 2 or above. The number of participants scoring 0-1 on the NIHSS at Day 30 was compared for both groups.
  • Modified Rankin Scale (mRS). [ Time Frame: Enrolment, Day 30 ] [ Designated as safety issue: No ]
    The mRS is a measure of global disability that has been widely applied for evaluating recovery from stroke. Scores range from 0 to 6, with higher scores indicating greater disability. A score of 0 indicates no residual symptoms; 1 = no significant disability/able to carry out all usual activities, despite some symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = death. The number of participants scoring 0-2 on the mRS at Day 30 was compared in both treatment groups.
To determine the efficacy of a single intravenous dose of NA-1 in reducing (1) the number of embolic strokes, (2) procedurally-induced vascular cognitive impairment, and (3) the frequency of large strokes. [ Time Frame: Enrolment, Day 1, Days 2-4, Day 30 ] [ Designated as safety issue: No ]
  • Volume of New FLAIR Lesions (MRI) - Ruptured Aneurysm Subjects [ Time Frame: Enrolment, Days 2-4 ] [ Designated as safety issue: No ]
    Volume of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose (pre-specified subgroup analysis)
  • Number of New DWI Lesions (MRI) - Ruptured Aneuryms Subjects [ Time Frame: Enrolment, Day 2-4 ] [ Designated as safety issue: No ]
    Number of new ischemic lesions as defined by DWI MRI at 12-95 hours postdose(pre-specified subgroup analysis)
  • Number of New FLAIR Lesions (MRI) - Ruptured Aneurysm Subjects [ Time Frame: Enrolment, Day 2-4 ] [ Designated as safety issue: No ]
    Number of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose(pre-specified subgroup analysis)
  • Volume of New DWI Lesions (MRI) - Ruptured Aneurysm Subjects [ Time Frame: Enrolment, Day 2-4 ] [ Designated as safety issue: No ]
    Volume of new DWI lesions as defined by MRI at 12-95 hours postdose(pre-specified subgroup analysis)
  • National Institutes of Health Stroke Scale (NIHSS) - Ruptured Aneurysm Subjects [ Time Frame: Enrolment, Day 30 ] [ Designated as safety issue: No ]
    The NIHSS is a standardized neurological method to measure disability and recovery after stroke. Scores range from 0 to 42, with higher scores indicating increasing severity. Scores were dichotomized into 0-1 (good outcome) versus 2 or above. The number of participants scoring 0-1 on the NIHSS at Day 30 was compared for participants with ruptured aneurysms in both treatment groups(pre-specified subgroup analysis).
  • Modified Rankin Scale (mRS)- Ruptured Aneurysm Subjects [ Time Frame: Enrolment, Day 30 ] [ Designated as safety issue: No ]
    The mRS is a measure of global disability that has been widely applied for evaluating recovery from stroke. Scores range from 0 to 6, with higher scores indicating greater disability. A score of 0 indicates no residual symptoms; 1 = no significant disability/able to carry out all usual activities, despite some symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = death. The number of participants scoring 0-2 on the mRS at Day 30 with ruptured aneurysms was compared in both treatment groups(pre-specified subgroup analysis).
Not Provided
 
Evaluating Neuroprotection in Aneurysm Coiling Therapy
A Phase II, Multicenter, Randomized, Fasting, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Male and Female Patients Undergoing Endovascular Repair of Brain Aneurysms

This is a randomized, double-blind, placebo-controlled, single-dose, design investigating the safety, tolerability and efficacy of NA-1, a peptide designed to reduce ischemic brain damage. Up to 200 male and female patients undergoing endovascular repair of brain aneurysm will be dosed with 2.60 mg/kg of NA-1 or placebo as a 10 minute intravenous infusion after completion of the endovascular procedure on Day 1 of the study period. Subjects will undergo interim procedures Days 2-4 and end-of study procedures on Day 30. Standard safety criteria will be analysed. Efficacy endpoints include the ability of NA-1 to: 1) reduce the volume of ischemic embolic strokes, 2) reduce the number of ischemic embolic strokes, 3) reduce vascular cognitive impairment, and 4) reduce the frequency of large strokes induced by the endovascular procedure. The plasma concentrations of NA-1 will also be analyzed.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Stroke
  • Drug: NA-1
    single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
  • Drug: Placebo
    single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
  • Experimental: NA-1
    20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
    Intervention: Drug: NA-1
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, Milot G, Clark WM, Macdonald RL, Kelly ME, Boulton M, Fleetwood I, McDougall C, Gunnarsson T, Chow M, Lum C, Dodd R, Poublanc J, Krings T, Demchuk AM, Goyal M, Anderson R, Bishop J, Garman D, Tymianski M; ENACT trial investigators. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012 Nov;11(11):942-50. doi: 10.1016/S1474-4422(12)70225-9. Epub 2012 Oct 8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
185
May 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria

  • A diagnosis of a ruptured or unruptured brain aneurysm deemed suitable for repair by neuroendovascular techniques involving intraluminal occlusion by detachable platinum coils, stent-assisted coiling, pipeline stent, balloon-assisted coiling, covered stent only, neck-bridge device, re-coiling, or re-treatment of a previously coiled/treated aneurysm. There are no restrictions on adjunctive devices. For patients with a ruptured aneurysm, endovascular repair must take place within 72 hours of the ictal haemorrhage.
  • If the aneurysm has ruptured, patient should be Grade I-III on the World Federation of Neurological Surgeons (WFNS) grading scale for subarachnoid hemorrhage. If the patient is intubated but alert and able to follow commands (at least a 2-step command), and is not kept intubated for neurological status (i.e., WFNS Grade IV or V), the patient is considered WFNS Grade III and is eligible for the trial.
  • Absence of ongoing ischemic symptoms such as transient ischemic attacks, minor strokes, stroke-in-evolution, or clinical evidence of cerebral vasospasm within 2 weeks prior to randomization. (If a CT scan, cerebral angiogram, or other imaging performed during the 2 weeks prior to randomization shows radiological vasospasm deemed by the treating physician to be potentially clinically significant, the subject is excluded.)
  • Brain MRI imaging (DWI and FLAIR sequences) within 2 weeks prior to the endovascular aneurysm repair procedure as detailed in Section 8.2. Imaging must not demonstrate any focal ischemic stroke defined as a new region of restricted diffusion and/or a focal area of reduced perfusion on a relative mean transit time (rMTT) or relative time to peak (rTTP) map
  • Male or female with a minimum age of 18 years on the day of enrolment.
  • Female subjects of childbearing potential: Negative pregnancy test. After enrolment, blood will be drawn from women of childbearing potential for a confirmatory test of pregnancy as evaluated by a serum B-hCG test. The definition of non-childbearing potential includes the following:

    • Surgically sterile (e.g., hysterectomy with or without oophorectomy; fallopian tube ligation; endometrial ablation), at least 30 days prior to signature of the Informed Consent form
    • At least 5 years post-menopause (i.e., 6 years post last menstrual period), or menopause confirmed by follicle-stimulating hormone (FSH) testing. Non-surgically sterile females or females with undocumented post-menopausal status must be willing to use a medically approved method of birth control for 3 months after completion of dosing.
  • Non-surgically sterile males or males with partners of childbearing potential must be willing to use condoms with spermicide for 3 months after completion of dosing.
  • Body weight less than or equal to 180 kg.
  • Normal or abnormal but not clinically significant findings in the

    • non-neurological physical examination
    • 12-lead ECG
    • PQ or PR interval less than or equal to 210 msec;
    • In unruptured aneurysm cases, QTc interval less than 450 msec for males or 470 msec for females. For ruptured aneurysm cases, QTc interval is not restricted.
    • vital signs
    • blood pressure between 80-180/50-100 mm Hg,
    • body temperature less than or equal to 38.5oC
  • Informed consent and availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed Informed Consent Form.

Exclusion Criteria

  • Dissecting or mycotic brain aneurysm. Fusiform or atherosclerotic intracerebral aneurysms may be eligible for the trial if endovascular treatment is planned with a goal of exclusion of the aneurysm from the circulation.
  • Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment.
  • Known history of life-threatening allergic reaction to any medication.
  • Chronic renal disease defined as a baseline serum creatinine > 150 umol/L.
  • Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.
  • Women who are breastfeeding.
  • Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol.
  • Pre-morbid (estimated) modified Rankin scale score of greater than 2.
  • Previous serious traumatic brain injury that would preclude the patient from completing the protocol or preclude MRI analysis of small strokes.
  • Patients with known HIV infection.
  • Patients who are unable to have an MRI scan for any reason.
  • Participation in a clinical trial with an investigational drug within 30 days preceding this study. Previous participation in the ENACT trial (e.g,, to treat a prior aneurysm), participation in another trial involving NA-1 or prior receipt of NA-1.
  • Any other medical condition that the site investigator deems would put the patient at excessive risk of participation in the study or an expected life expectancy less than 1 year or that would result in inability to collect clinical outcomes at 30 days.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00728182
3302 (NA-1-002)
Yes
NoNO Inc.
NoNO Inc.
Arbor Vita Corporation
Principal Investigator: Michael Hill, M.D. Foothills Medical Centre, University of Calgary
NoNO Inc.
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP